Navigation Links
Positive Aggrastat Results Featured in the Journal of the American,College of Cardiology

Protocol for New Aggrastat Study in American Heart Journal


WINNIPEG, Manitoba - (July 11, 2007) Medicure Inc. (TSX:MPH; Amex:MCU), a cardiovascular focused, biopharmaceutical company, today announced that the two-year, follow-up results from the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare Metal Stent In Acute Myocardial Infarction) study were published in the July edition of the Journal of the American College of Cardiology (JACC).


The article, titled, "Two-Year Clinical Follow-Up After Sirolimus-Eluting Versus Bare-Metal Stent Implantation Assisted by Systematic Glycoprotein IIb/IIIa Inhibitor Infusion in Patients With Myocardial Infarction", outlines the potential benefit of AGGRASTATR (tirofiban hydrochloride) plus sirolimus-eluting stent (SES) versus ReoproR (abciximab) plus bare-metal stent (BMS) in the prevention of the cumulative incidence of death, myocardial infarction (MI), or target vessel revascularization (TVR) in acute myocardial infarction patients after two years.


At two years, the cumulative incidence of death, MI, or TVR was lower in the AGGRASTATR-SES group compared with the ReoproR-BMS group (24.2% vs. 38.6%, p@038). This statistically significant outcome at two years is similar to the previously reported eight month results that were published in The Journal of the American Medical Association (May 2005).


The positive results from STRATEGY were the impetus for an ongoing larger factorial design study titled MULTI-STRATEGY (Multicentre Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab and Sirolimus-Eluting Stent Versus Base Metal Stent in Acute Myocardial Infarction). The MULTI-STRATEGY protocol was published in the July edition of the American Heart Journal.


This 600-patient study will further assess AGGRASTATR-S
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Protox Announces Positive Clinical Data from Prostate Cancer Study
4. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
5. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
6. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
7. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
11. Alkermes Announces Positive Results from Phase 1/2 Clinical Study of ALKS 29
Post Your Comments:
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. ... the closing of its offering of $125 million aggregate ... (the "Notes").  The Notes were offered and sold only ... the Securities Act of 1933, as amended (the "Securities ... fixed rate of 3.75% per year, payable semiannually in ...
(Date:12/15/2014)... Research and Markets ( http://www.researchandmarkets.com/research/vt6973/mems_gyroscopes ... "MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... made a lot of progress in the past ... now accepted in high-reliability environments, and are even ...
(Date:12/15/2014)... HERZLIYA PITUACH, Israel , Dec. 15, 2014 ... IMNP ) announced today that its Board of Directors has ... Daniel Teper who continues as Chief Executive Officer ... Board of Directors since 2013. Immune,s new Chairman, ... represent the interest of shareholders and to continue to support ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 2Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 3Immune Pharmaceuticals Elects Daniel Kazado as New Chairman of the Board. 4
... 2011 Pharmacyclics, Inc. (Nasdaq: PCYC ), ... small molecule drugs for the treatment of cancer and ... host a conference call and live audio webcast on ... the company,s second quarter fiscal 2011 financial and operational ...
... Health today announced that its board of directors has approved a ... to shareholders of record on April 1. This marks the 106th ... Cardinal Health Headquartered in Dublin, Ohio, Cardinal ... health care services company that improves the cost-effectiveness of ...
Cached Medicine Technology:Pharmacyclics to Announce Second Quarter Fiscal 2011 Results and Host a Conference Call on February 4, 2011 2Cardinal Health Declares Regular Quarterly Dividend 2
(Date:12/17/2014)... -- Expectant parents should leave prenatal picture-taking to medical ... Use of ultrasound imaging and heartbeat monitors to get ... agency warns. "Although there is a lack ... and heartbeat monitors, prudent use of these devices by ... FDA biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... America, and work commitment is a big reason why, new ... said Dr. Mathias Basner, an assistant professor of sleep and ... of Medicine. A time-use survey of nearly 125,000 Americans, ... main activity exchanged for sleep. Short sleepers -- those who ...
(Date:12/15/2014)... 15, 2014 South Florida’s leading urgent care ... can be a daze of hassle, hustle, and bustle that ... decking halls, to burns when making special meals and heartburn ... can happen at any time. To prevent this season of ... made a list of helpful and healthful holiday tips to ...
(Date:12/15/2014)... News) -- Expert pilots process visual information more efficiently ... better decisions during landings, a new study shows. ... pilots to master, and 36 percent of all airplane ... final approach and landing. Researchers monitored the brain ... pilots while they were at the controls of a ...
(Date:12/15/2014)... 15, 2014 At the leading, long-established ... AutismOne and Focus Autism will welcome ... research on the effects of toxins to children’s health, ... information. , Luminaries such as Dr. Lucija Tomljenovic ... with esteemed, credentialed colleagues of the United States to ...
Breaking Medicine News(10 mins):Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Work Steals Valuable Sleep Time, Study Finds 2Health News:Work Steals Valuable Sleep Time, Study Finds 3Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:Study Shows Why Expert Pilots Are Experts 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3
... CITY, Iowa, May 6 Quatro Composites, ... composite products, has been,awarded ISO 9001:2000 and ... of its facilities, located in Orange City, ... of the AS9100 quality management,system., "Receiving ...
... 20% Year-Over-Year ... Cost Reduction Efforts Show ... Ends the Quarter with $10.5 Million in Cash, MONROVIA, Calif., May ... and marketer of,minimally invasive ophthalmic products, today reported good progress during,its first ...
... finds short-term dysfunction while awaiting operation rarely turns ... -- Few patients who have short-term kidney dysfunction ... problems once they have their transplant, says a ... have kidney dysfunction while awaiting liver transplantation, which ...
... Demonstrate to Protect Their Voice & Vote at,SEIU Hearing, ... the direction of the Service Employees International Union (SEIU),intensified ... was held to,determine the fate of more than 60,000 ... West (UHW). UHW represents 150,000,caregivers in hospitals, clinics, nursing ...
... Management: Making a ... Difference Today and Tomorrow, HARRISBURG, Pa., ... Officer, will deliver the clinical keynote,address on Wednesday afternoon, May ... World of Care Management. Dr. Petrulis will,present Care Management: Making ...
... aid couples trying to conceive , , TUESDAY, May 6 ... the lubricant they use wisely because some lubricants can ... commercial lubricants are toxic to sperm, and couples who ... they want," said study author Dr. William H. Kutteh, ...
Cached Medicine News:Health News:Quatro Composites Receives ISO 9001:2000 and AS9100:2004 Certification 2Health News:STAAR Surgical Reports Solid First Quarter Progress 2Health News:STAAR Surgical Reports Solid First Quarter Progress 3Health News:STAAR Surgical Reports Solid First Quarter Progress 4Health News:STAAR Surgical Reports Solid First Quarter Progress 5Health News:STAAR Surgical Reports Solid First Quarter Progress 6Health News:STAAR Surgical Reports Solid First Quarter Progress 7Health News:STAAR Surgical Reports Solid First Quarter Progress 8Health News:STAAR Surgical Reports Solid First Quarter Progress 9Health News:STAAR Surgical Reports Solid First Quarter Progress 10Health News:STAAR Surgical Reports Solid First Quarter Progress 11Health News:STAAR Surgical Reports Solid First Quarter Progress 12Health News:Kidney Trouble Short-Lived in Most Liver Transplant Patients 2Health News:SEIU Retaliates Against California Caregivers & Democratic Reform Movement 2Health News:KePRO's Chief Medical Officer to Deliver Clinical Keynote Address 2Health News:Researchers Find Lubricant Doesn't Hinder Fertility 2Health News:Researchers Find Lubricant Doesn't Hinder Fertility 3
... Finntips have been designed to optimize the ... of our tip products is widely recognized ... range has been extended over the years ... standard and special tips including filter tips, ...
... Finntip Filters are ideal for ... or for any work where ... are designed for pipetting DNA/RNA ... and other. For applications requiring ...
... a safe alternative to using positive displacement ... such as PCR(a), pipetting radioactive materials and ... excellent for tissue culture, gel loading, serological ... aerosol contaminants and liquids from reaching the ...
Inquire...
Medicine Products: